Detection of serum microRNA in esophageal squamous cell carcinoma with neoadjuvant chemoradiotherapy sensitivity and its clinical application value
YANG Jingrong1,2 WU Jian2 YE Shixin2 LIAN Duohuang2 ZENG Zhiyong1,2▲
1.The Second Military Medical University, Shanghai 200433, China;
2.Department of Thoracic and Cardiovascular Surgery, Fuzhou General Hospital of Nanjing Military Command, Fujian Province, Fuzhou 350025, China
Abstract：Objective To investigate the relationship between serum microRNA(miRNA) and neoadjuvant radiotherapy (NCRT) for esophageal squamous cell carcinoma and its predictive value. Methods From January 2015 to December 2016, 30 patients with preoperative NCRT cT3-4N0 esophageal squamous cell carcinoma admitted to Fuzhou General Hospital of Nanjing Military Command were selected. Peripheral blood of the patients were collected before NCRT. According to the postoperative pathological results, the patients were divided into the sensitive group and the resistance group, with 15 cases in each group. The differentially expressed serum mirnas in the NCRT sensitive group and the resistance group were detected by miRNA expression profile microarray. Then, the sample size was expanded for real-time fluorescence quantitative PCR to verify the initially screened serum mirnas. The relationship between the efficacy of miRNA and NCRT was analyzed and verified. Subject operating characteristic (ROC) curves were used to evaluate the value of miRNA in predicting the efficacy of NCRT. Results A total of 16 differentially expressed mirnas were detected in the serum of the two groups, among which miRNA-23, miRNA-211 and miRNA-323 were verified by qRT-PCR, and the differences were statistically significant (P ＜ 0.05). The area under the curve of the short-term efficacy of the three factors and esophageal squamous cell carcinoma NCRT was 0.764, 0.880 and 0.707, respectively. Conclusion The evaluation of miRNA-23, miRNA-211 and miRNA-323 in the short-term efficacy of esophageal squamous cell carcinoma NCRT may have certain predictive value.
[1] Alderson D，Cunningham D，Nankivell M，et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin，cisplatin，and capecitabine followed by resection in patients with oesophageal adenocarcinoma （UK MRC OE05）：an open-label，randomised phase 3 trial [J]. Lancet Oncol，2017，18（9）：1249-1260.
[2] Tang H，Tan L，Shen Y，et al. CMISG1701：a multicenter prospective randomized phase Ⅲ clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma （cT3-4aN0-1M0） （NCT03001596） [J]. BMC Cancer，2017，17（1）：450.
[3] Skinner HD，Lee JH，Bhutani MS，et al. A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma [J]. Cancer，2014，120（23）：3635-3641.
[4] Bibby BAS，Reynolds JV，Maher SG. MicroRNA-330-5p as a Putative Modulator of Neoadjuvant Chemoradiotherapy Sensitivity in Oesophageal Adenocarcinoma [J]. Plos One，2015，10（7）：e0134180.
[5] Odenthal M，Hee J，Gockel I，et al. Serum microRNA profiles as prognostic/predictive markers in the multimodality therapy of locally advanced adenocarcinomas of the gastroesophageal junction [J]. Int J Cancer，2015，137（1）：230-237.
[6] Ko MA，Zehong G，Virtanen C，et al. MicroRNA expression profiling of esophageal cancer before and after induction chemoradiotherapy [J]. Ann Thorac Surg，2012，94（4）：1094-1103.
[7] Shafiee M，Aleyasin SA，Vasei M，et al. Down-Regulatory Effects of miR-211 on Long Non-Coding RNA SOX2OT and SOX2 Genes in Esophageal Squamous Cell Carcinoma [J]. Cell J，2016，17（4）：593-600.
[8] Zhang S，Ma H，Zhang D，et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Ezrin/Fak/Src signaling [J]. Cell Death Dis，2018，9（7）：742.
[9] Shridhar R，Hoffe SE，Almhanna K，et al. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy [J]. Ann Surg Oncol，2013，20（9）：3038-3043.
[10] Wu TT，Chirieac LR，Abraham SC，et al. Excellent interobserver agreement on grading the extent of residual carcinoma after preoperative chemoradiation in esophageal and esophagogastric junction carcinoma：a reliable predictor for patient outcome [J]. Am J Surg Pathol，2007， 31（1）：58-64.
[11] H?觟lscher AH，Drebber U，Schmidt H，et al. Prognostic Classification of Histopathologic Response to Neoadjuvant Therapy in Esophageal Adenocarcinoma [J]. Ann Surg，2014，260（5）：779-785.
[12] Fakhrian K，Ordu AD，Lordick F，et al. Long-term outcomes of trimodality treatment for squamous cell carcinoma of the esophagus with cisplatin and/or 5-FU：more than 20 years′ experience at a single institution [J]. Strahlenther Onkol，2014，190（12）：1133-1140.
[13] Wu AJ，Goodman KA. Clinical tools to predict outcomes in patients with esophageal cancer treated with definitive chemoradiation：are we there yet? [J]. J Gastro Oncol，2015， 6（1）：53-59.
[14] Toxopeus ELA，Nieboer D，Shapiro J，et al. Nomogram for predicting pathologically complete response after neoadjuvant chemoradiotherapy for oesophageal cancer [J]. Radiother Oncol，2015，115（3）：392-398.
[15] Asuthkar S，Velpula KK，Chetty C，et al. Epigenetic regulation of miRNA-211 by MMP-9 governs glioma cell apoptosis，chemosensitivity and radiosensitivity [J]. Oncotarget，2012，3（11）：1439-1454.
[16] Gao Q，Zheng J. microRNA-323 upregulation promotes prostate cancer growth and docetaxel resistance by repressing p73 [J]. Biomed Pharmacother，2018，97：528-534.
[17] Wang C，Liu P，Wu H，et al. MicroRNA-323-3p inhibits cell invasion and metastasis in pancreatic ductal adenocarcinoma via direct suppression of SMAD2 and SMAD3 [J]. Oncotarget，2016，7（12）：14912-14924.
[18] Shang J，Yang F，Wang Y，et al. MicroRNA-23a antisense enhances 5-fluorouracil chemosensitivity through APAF-1/caspase-9 apoptotic pathway in colorectal cancer cells [J]. J Cell Biochem，2014，115（4）：772-784.
[19] 金爱红，周霞平，周凤珍.抑制miR-23a表达增强卵巢癌顺铂敏感性的分子机制[J].南方医科大学学报，2015（1）：125-128.
[20] Li B，Sun M，Gao F，et al. Up-regulated expression of miR-23a/b targeted the pro-apoptotic Fas in radiation-induced thymic lymphoma [J]. Cell Physiol Biochem，2013， 32（6）：1729-1740.
2019, Vol. 16 
京公网安备 11010502046598号